WG
CSTL icon

Winton Group’s Castle Biosciences CSTL Stock Holding History

Winton Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,869
Closed -$258K – 857
2025
Q1 		$258K Buy
+12,869
New +$319K 0.02% 598
2024
Q4 		– Sell
-16,526
Closed -$471K – 651
2024
Q3 		$471K Buy
+16,526
New +$421K 0.03% 453
2021
Q4 		– Sell
-4,607
Closed -$306K – 1093
2021
Q3 		$306K Buy
4,607
+479
+12% +$33.7K 0.02% 1083
2021
Q2 		$303K Buy
4,128
+26
+0.6% +$1.72K 0.02% 1174
2021
Q1 		$281K Sell
4,102
-2,440
-37% -$183K 0.02% 1168
2020
Q4 		$439K Buy
6,542
+1,057
+19% +$57.3K 0.03% 854
2020
Q3 		$282K Buy
+5,485
New +$244K 0.01% 1265

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Winton Group's CSTL Position: Q2 2025 in Review

Winton Group sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 12,869 shares — an estimated $258K sold.

Winton Group first reported a position in CSTL in Q3 2020 and held it in 7 quarters. The position peaked at $471K in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Winton Group reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Winton Group sold 12,869 Castle Biosciences shares in Q2 2025, an estimated $258K.
  • Winton Group first reported a position in Castle Biosciences in Q3 2020 and held it in 7 quarters.
  • Winton Group's Castle Biosciences position peaked at $471K in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Winton Group's 13F filing for Q2 2025, filed 14 Aug 2025.